Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Mouse Monoclonal [clone EOS9.1] (IgM,k) to Human CD95 / FAS
Human CD95 / FAS
Human (tested or 100% immunogen sequence identity)
IgM,k Monoclonal [EOS9.1]
Specificity and Use
CD95 / FAS antibody was raised against human FAS
The EOS9.1 antibody has been tested by flow cytometric analysis of human peripheral blood leukocytes and has also been tested for its ability to induce apoptosis of Jurkat cells. This can be used at less than or equal to 1 ug per test. A test is defined as the amount (ug) of antibody that will stain a cell sample in a final volume of 100 ul. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
PBS, pH 7.2, 500 mM sodium chloride, 0.09% sodium azide
CD95 / FAS is a member of the TNF-receptor superfamily. This receptor contains a death domain. It has been shown to play a central role in the physiological regulation of programmed cell death, and has been implicated in the pathogenesis of various malignancies and diseases of the immune system. The interaction of this receptor with its ligand allows the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase 8, and caspase 10.
Jurkat cells were treated for 6 hours with 0.1 ug/ml Functional Grade Purified EOS9.1. Induction of apoptosis in these cells was determined by staining with PI and anti-BrdU-FITC using the Apo-BrdUTM kit. As shown in plot B, approximately 60% of cells underwent Fas-induced apoptosis following antibody treatment.
Jurkat cells were treated for 6 hours with medium alone. Induction of apoptosis in these cells was determined by staining with PI and anti-BrdU-FITC using the Apo-BrdUTM kit.
Requested From: United States
Date Requested: 10/23/2016